Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

被引：0
作者：
Masahiro Morimoto
Hidetaka Matsumoto
Kensuke Mimura
Hideo Akiyama
机构：
[1] Gunma University,Department of Ophthalmology
[2] School of Medicine,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2017年 / 255卷
关键词：
Age-related macular degeneration; Polypoidal choroidal vasculopathy; Anti-vascular endothelial growth factor; Aflibercept; Treat-and-extend regimen; Macular thickness; Choroidal thickness; Optical coherence tomography; Fluorescein angiography; And indocyanine green angiography;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1891 / 1897
页数：6
相关论文
共 195 条
  • [1] Yannuzzi LA(1997)The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy Arch Ophthalmol 115 478-485
  • [2] Ciardella A(2016)Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians Prog Retin Eye Res 53 107-139
  • [3] Spaide RF(2007)Clinical characteristics of exudative age-related macular degeneration in Japanese patients Am J Ophthalmol 144 15-22
  • [4] Rabb M(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
  • [5] Freund KB(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
  • [6] Orlock DA(2009)A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study Am J Ophthalmol 148 43-58
  • [7] Wong CW(2012)HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 1175-1183
  • [8] Yanagi Y(2013)Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2292-2299
  • [9] Lee WK(2007)Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 679-680
  • [10] Ogura Y(2015)Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen Am J Ophthalmol 159 3-8
12345678910